WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released its third-quarter 2024 financial results, ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...

Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191, an investigational therapy, aimed at treating ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and ...

Hope Biosciences' stem cell therapy led to improved scores on a quality-of-life test for MS patients in a small clinical trial.

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Palvella Therapeutics announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all types of MS.

Werewolf Therapeutics (HOWL) shared clinical and preclinical data at the 2024 Society for Immunotherapy of Cancer’s 39th Annual Meeting, ...

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...